Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Pacific Biosciences yesterday and set a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyle Mikson CFA has given his Buy rating due to a combination of factors including Pacific Biosciences’ strong performance in the second quarter of 2025, where the company exceeded revenue expectations. This was largely driven by increased placements of their Revio and Vega systems, with the latter showing significant momentum by expanding the adoption of HiFi technology into numerous labs. Additionally, the development of multi-use SMRT cells is expected to enhance the company’s competitive edge by reducing costs and improving margins.
Kyle Mikson CFA also noted that despite challenges such as NIH budget uncertainties and U.S./China tariffs, Pacific Biosciences has narrowed its 2025 revenue guidance while maintaining a consistent midpoint. The company’s strategic initiatives, including cost-cutting measures and a focus on long-read technology, are seen as positive steps towards achieving cash flow positivity by 2027. Overall, the analyst remains optimistic about the company’s future prospects and believes the current stock price does not fully reflect its potential.
In another report released today, Bernstein also maintained a Buy rating on the stock with a $1.70 price target.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PACB in relation to earlier this year.